1. Home
  2. ENSC vs BDRX Comparison

ENSC vs BDRX Comparison

Compare ENSC & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ensysce Biosciences Inc.

ENSC

Ensysce Biosciences Inc.

HOLD

Current Price

$0.27

Market Cap

1.7M

Sector

Health Care

ML Signal

HOLD

Logo Biodexa Pharmaceuticals plc

BDRX

Biodexa Pharmaceuticals plc

HOLD

Current Price

$3.51

Market Cap

2.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENSC
BDRX
Founded
2003
2000
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7M
2.0M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
ENSC
BDRX
Price
$0.27
$3.51
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.1M
193.7K
Earning Date
05-13-2026
09-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$55.01
N/A
Revenue Next Year
$1,033.97
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$0.60
52 Week High
$2.75
$11.88

Technical Indicators

Market Signals
Indicator
ENSC
BDRX
Relative Strength Index (RSI) 30.08 51.78
Support Level N/A $2.94
Resistance Level $0.44 $4.39
Average True Range (ATR) 0.04 0.38
MACD -0.01 -0.09
Stochastic Oscillator 17.58 24.15

Price Performance

Historical Comparison
ENSC
BDRX

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

About BDRX Biodexa Pharmaceuticals plc

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.

Share on Social Networks: